New Biomaterial Approach Shows Promise for Stem Cell Islet Transplants in Type 1 Diabetes

For decades, researchers have explored transplanting insulin-producing cells (islets) to restore blood sugar control in people with Type 1 diabetes. Stem cell-derived islets offer a potentially unlimited source for such transplants. However, getting these cells to work reliably after transplant has proven difficult, and traditional approaches often require patients to take immune-suppressing medications.

A new international study focused on solving this problem by investigating whether specially designed biomaterial scaffolds could support transplanted islets and eliminate the need for immune suppression.

Researchers from universities and research organizations in Australia and the United States collaborated on this study, which was published in the journal Diabetology. They engineered scaffolds that incorporated extracellular matrix (ECM)—structural material derived from human pancreatic tissue that had been specially processed to remove cells.

The team tested whether these ECM-enriched scaffolds could support the function of encapsulated stem cell-derived islets within a removable delivery system. Encapsulation—placing cells inside a protective barrier—is designed to shield transplanted cells from the immune system without requiring patients to take immunosuppressive drugs.

The findings were encouraging: when ECM was incorporated into the scaffold, the implanted islets performed as well as islets delivered using other encapsulation methods without a scaffold. This suggests that the biomaterial design and the tissue microenvironment created by the scaffold actively supported islet function.

Importantly, the scaffolds used in the study were designed to be removable. This feature could make future treatments safer and more flexible, since retrieval of the system would be possible if needed.

These results add to our understanding of how to support transplanted islet cells. They highlight that the environment surrounding transplanted cells—created through biomaterial design—plays a crucial role in their success.

While this research is early-stage and conducted in a laboratory setting, it represents progress toward developing transplant approaches that could work without requiring patients to take immunosuppressive medications long-term. Further research and clinical testing will be needed before such treatments become available to patients.

Origin: prnewswire.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.